Dr. Steven Lipkin, MD, PhD, FACMG serves as Ambry's Chief Medical Officer. An internationally renowned physician-scientist and expert in hereditary cancer research and genetic diseases, Dr. Lipkin brings fresh insights and experience in clinical genetics, translational medicine, and academic research. 

Dr. Lipkin’s groundbreaking career spans pioneering discoveries in cancer predisposition genes, including MLH3 and ETV6, mechanistic insights into DNA repair, and leading innovative, NIH-funded research in cancer precision prevention and immunoprevention. 

Before joining Ambry, Dr. Lipkin served as the Gladys and Roland Harriman Professor of Medicine and Vice Chair for Research, Department of Medicine at Weill Cornell Medicine, where annual research enterprise revenues more than doubled during his tenure there. He also directed the Adult and Cancer Genetics Clinic and the Program in Mendelian Genetics. He has guided advancements in genetic medicine through key advisory roles for the US Food and Drug Administration on the Molecular and Clinical Genetics Panel.

Dr. Lipkin also contributes to the scientific community as a prolific author featured in high impact journals such as Nature Genetics, Cell, and Science, and is an elected member of the American Society for Clinical Investigation. He is also the author of The Age of Genomes: Tales from the Front Lines of Genetic Medicine (Beacon Press).

He earned his undergraduate degree from Princeton University (summa cum laude), his MD/PhD from UC San Diego, his Internal Medicine residency at Duke University Medical Center, and trained in Clinical Genetics at the National Human Genome Research Institute, where researched in the laboratory of Francis Collins. His pioneering research has advanced our understanding of Lynch syndrome, the most common gastrointestinal cancer predisposition syndrome, was among the first to elucidate cancer-initiating cells, led to the first immune-competent mouse models of human cancer, and identified several cancer predisposition genes.